Improving the Reporting of Adverse Drug Reactions in the Hospital Setting

被引:19
作者
Pushkin, Richard [1 ]
Frassetto, Lynda
Tsourounis, Candy [3 ]
Segal, Eleanor S. [4 ]
Kim, Stephanie [2 ]
机构
[1] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA
[2] Actel Pharmaceut US Inc, Regulatory Affairs, San Francisco, CA USA
[3] Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA
[4] Actel Pharmaceut Ltd, Allschwil, Switzerland
关键词
adverse drug reactions; adverse events; drug safety; hospital setting; pharmacovigilance; EUROPEAN POSTMARKETING SURVEILLANCE; SAFETY EXPERIENCE; UNITED-STATES; EVENTS; PHARMACOVIGILANCE; HEPATOTOXICITY; PHARMACISTS; BOSENTAN; INTERVENTION; PHYSICIANS;
D O I
10.3810/pgm.2010.11.2233
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The US Food and Drug Administration (FDA) is perceived by the public as having a substantial responsibility to ensure drug safety; however, the FDA has limited resources for active surveillance and relies on voluntary reporting of adverse events and potential adverse drug reactions. Studies have shown that underreporting of adverse events and adverse drug reactions is widespread. Furthermore, a review of several studies demonstrates that most adverse drug reactions are reported by pharmacists and nurses, with physicians reporting the fewest. The hospital setting, with its clearly defined patient population observed around the clock, is an ideal setting in which to identify potential adverse drug reaction signals and to report them to either the drug manufacturer or the FDA. In this article we describe the present system for addressing adverse events, obstacles to reporting them, and the important role any hospital physician could play in reporting adverse events and potential adverse drug reactions.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 72 条
[1]  
Aagaard Lise, 2009, BMC Clin Pharmacol, V9, P4, DOI 10.1186/1472-6904-9-4
[2]   The effect of electronic prescribing on medication errors and adverse drug events: A systematic review [J].
Ammenwerth, Elske ;
Schnell-Inderst, Petra ;
Machan, Christof ;
Siebert, Uwe .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2008, 15 (05) :585-600
[3]  
[Anonymous], 1995, Am J Health Syst Pharm, V52, P417
[4]   Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: Results from the European postmarketing surveillance program [J].
Beghetti, Maurice ;
Hoeper, Marius M. ;
Kiely, David G. ;
Carlsen, Joern ;
Schwierin, Barbara ;
Segal, Eleanor S. ;
Humbert, Marc .
PEDIATRIC RESEARCH, 2008, 64 (02) :200-204
[5]   ATTITUDINAL SURVEY OF ADVERSE DRUG REACTION REPORTING BY MEDICAL PRACTITIONERS IN THE UNITED-KINGDOM [J].
BELTON, KJ ;
LEWIS, SC ;
PAYNE, S ;
RAWLINS, MD ;
WOOD, SM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :223-226
[6]   Adverse drug reactions in United States hospitals [J].
Bond, CA ;
Raehl, CL .
PHARMACOTHERAPY, 2006, 26 (05) :601-608
[7]   Assessing explicit error reporting in the narrative electronic medical record using keyword searching [J].
Cao, H ;
Stetson, P ;
Hripcsak, G .
JOURNAL OF BIOMEDICAL INFORMATICS, 2003, 36 (1-2) :99-105
[8]  
Craigle V., 2007, J Med Libr Assoc, V95, P224, DOI [10.3163/1536-5050.95.2.224, DOI 10.3163/1536-5050.95.2.224]
[9]   Pharmacologic therapy for type 2 diabetes mellitus [J].
DeFronzo, RA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303
[10]   Adverse drug reactions: definitions, diagnosis, and management [J].
Edwards, IR ;
Aronson, JK .
LANCET, 2000, 356 (9237) :1255-1259